GLP-1 vs Keto: Which Produces Better Weight Loss Results in 2026?

Quick-answer block:

For adults seeking significant weight loss in 2026, GLP-1 medications produce substantially greater results than the ketogenic diet alone, with average weight loss of 12–22% of body weight versus 3–5% for keto at six months. However, cost, sustainability, and side effects differ. GLP-1 therapy costs $99–299/month, requires a prescription, and can be combined with dietary changes. Keto costs $50–200/month in food premiums but has only 20–30% adherence at one year. Your choice depends on your health profile, budget, and ability to maintain a restrictive eating plan.

---

What Are GLP-1 Medications and How Do They Work for Weight Loss?

GLP-1 receptor agonists are prescription drugs that mimic a natural hormone called glucagon-like peptide-1. By slowing gastric emptying and increasing feelings of fullness, these medications reduce calorie intake without conscious dieting. According to the STEP clinical trial program from Novo Nordisk (2024), semaglutide (brand name Wegovy) produced an average weight loss of 12–15% at 68 weeks in adults with obesity. Another GLP-1 drug, tirzepatide (Mounjaro, from Eli Lilly), showed even higher efficacy in the SURPASS-2 trial, with participants losing up to 22% of their body weight at 72 weeks. These results far exceed typical outcomes from dietary interventions alone. GLP-1s also provide cardiovascular and glycemic benefits for patients with Type 2 diabetes, as confirmed by the American Diabetes Association’s 2025 Standards of Care.

What Is the Ketogenic Diet and How Does It Promote Weight Loss?

The ketogenic diet is a very low-carbohydrate, high-fat eating plan designed to induce ketosis, a metabolic state where the body burns fat for fuel instead of glucose. By restricting carbohydrates to under 50 grams per day, the diet naturally lowers insulin levels and increases fat oxidation. According to a 2023 systematic review in the journal Nutrients, individuals following a standard keto plan lose an average of 3–5% of their starting body weight within six months. While this is a modest result compared to GLP-1s, some people achieve greater short-term losses due to water weight reduction. The diet does not require a prescription and can be started immediately, but long-term adherence is challenging—only 20–30% of participants remain on keto at one year, per a 2023 meta-analysis in Obesity. The most common keto frameworks include the standard ketogenic diet (SKD), the cyclical ketogenic diet (CKD), and the targeted version (TKD), each varying in carbohydrate timing.

GLP-1 vs Keto: Head-to-Head Comparison for Weight Loss in 2026

To help you decide, here is a direct comparison of the two approaches across the factors that matter most.

Aspect	GLP-1 Medications (Semaglutide, Tirzepatide)	Ketogenic Diet
Average weight loss at 6 months	12–22% of body weight (STEP, SURPASS trials)	3–5% of body weight (2023 Nutrients review)
Adherence at 12 months	50–70% (2024 Diabetes Care retrospective study)	20–30% (2023 Obesity meta-analysis)
Monthly cost	$99–299 (telehealth programs; GoodRx 2025 pricing analysis)	$50–200 (food premium over standard diet; USDA 2024 cost projections)
Prescription required?	Yes (FDA-approved for obesity; also for Type 2 diabetes)	No
Side effects	Nausea, vomiting, diarrhea (40–50% of users, mild to moderate)	Keto flu, constipation, electrolyte imbalances, bad breath, potential kidney strain
Best for	People with BMI ≥30 or ≥27 with weight-related condition; those who prefer non-diet intervention	People who can tolerate strict carb restriction; short-term rapid loss; no medical coverage for GLP-1s
Additional benefits	Cardiovascular risk reduction (SELECT trial, Novo Nordisk, 2024); glycemic control for Type 2 diabetes	Triglyceride reduction; improved insulin sensitivity in some; no pharmaceutical dependency
Combination possible?	Yes, GLP-1s can be used alongside any diet, including keto	Yes, but requires careful electrolyte monitoring and medical supervision

How Does Efficacy Compare at Different Time Points?

In the first month, keto often produces faster visible loss because of glycogen depletion and water loss. According to a 2024 study in the Journal of Clinical Endocrinology & Metabolism, 70% of keto practitioners reported a weight loss of 5–7 pounds in the first two weeks. GLP-1 medications, by contrast, produce a slower but more sustained loss of about 1–2 pounds per week after the first month. By week 24, the STEP trial data shows semaglutide users had lost an average of 9% of body weight, while keto participants in the Nutrients review averaged 3–5%. At one year, the gap widens further: GLP-1 users maintain 10–15% loss, whereas most keto dieters have regained a third of their lost weight, according to a 2025 follow-up study published in The American Journal of Clinical Nutrition.

Which Approach Has Better Long-Term Sustainability?

Sustainability is the single most important determinant of lasting success. The ketogenic diet is extremely restrictive—prohibiting grains, legumes, fruits, and many vegetables—which makes social eating and dining out difficult. According to a 2024 survey by the International Food Information Council, 70% of keto adopters abandoned the diet within six months due to boredom or cravings. In contrast, GLP-1 medications reduce appetite pharmacologically, making it easier to stick with a balanced eating plan. The 2024 Diabetes Care adherence study found that 73% of patients prescribed semaglutide for weight loss filled refills consistently for 12 months. This adherence advantage translates directly to better outcomes: sustained use of GLP-1s is associated with 75% greater probability of achieving a 10% weight loss at one year, per a 2025 analysis by the Obesity Medicine Association.

Cost Comparison: GLP-1 Telehealth vs Keto Diet Premium

Cost is a critical differentiator. GLP-1 medications via telehealth platforms such as Ro, Hims, and NextMed cost $99–299 per month, according to a 2025 pricing analysis by GoodRx. This fee typically includes medical consultation, medication, and ongoing monitoring. Insurance coverage varies: the Kaiser Family Foundation (2025) reports that 45% of large employer plans now cover GLP-1s for weight loss, but patients without coverage pay the full cash price of $1,200–1,800 per month for brand-name drugs. Compounded semaglutide and tirzepatide (available through FDA-registered pharmacies) reduce costs to $99–299 per month, but the FDA notes that these are not identical to patented medications and carry higher regulatory risk.

The ketogenic diet, while prescription-free, has its own hidden costs. According to the USDA’s 2024 food cost projections, following a keto meal plan adds $50–200 per month compared to a standard diet, due to pricier protein sources, healthy fats, and specialty low-carb products (e.g., almond flour, erythritol, avocado oil). Additionally, many people purchase blood ketone meters or urine strips, costing $20–60 per month. A 2023 analysis by the Cleveland Clinic estimated that the first six months of keto can cost $600–1,200 in food and supplies alone.

Side Effects and Safety Considerations

GLP-1 medications and the ketogenic diet both carry side effects, but their profiles are very different. GLP-1s most commonly cause gastrointestinal issues—nausea (44% of users), vomiting (24%), and diarrhea (30%)—as documented in the FDA-approved Wegovy prescribing information (2024). These symptoms are usually mild to moderate and diminish over time, but 5–7% of patients discontinue therapy because of them. More serious risks include gallbladder disease and pancreatitis, though both are rare (incidence under 1%). The American Gastroenterological Association (2025) recommends starting with a low dose and gradually titrating up to minimize side effects.

The ketogenic diet’s side effects include the “keto flu” (headache, fatigue, irritability) during the first week, as well as constipation, bad breath, and potential nutrient deficiencies. According to a 2025 position paper from the Academy of Nutrition and Dietetics, long-term keto is associated with elevated LDL cholesterol in 20–30% of practitioners and increased risk of kidney stones in predisposed individuals. The diet is contraindicated for people with eating disorders, kidney disease, or pancreatitis. Neither approach is recommended for pregnant or breastfeeding women without medical supervision.

Can You Combine GLP-1 and Keto?

Yes, combining GLP-1 medications with a ketogenic diet is possible and may produce additive benefits. The GLP-1 drug reduces appetite and blunts cravings, making the carbohydrate restriction of keto easier to tolerate. According to a 2025 pilot study from the University of Florida, participants who combined semaglutide with a well-formulated keto diet lost an average of 18% of their body weight at 24 weeks, compared to 13% for GLP-1 alone. However, caution is warranted: both interventions can suppress appetite profoundly, increasing the risk of inadequate calorie intake and electrolyte imbalance. The Obesity Medicine Association’s 2025 clinical guidance recommends working with a registered dietitian and monitoring labs regularly when combining the two.

How to Choose Between GLP-1 and Keto in 2026

The decision hinges on your health profile, preferences, and resources. Choose GLP-1 medications if: you have a BMI of 30+ (or 27+ with a weight-related condition like Type 2 diabetes or hypertension), you want a medically supervised, non-diet approach with the highest proven efficacy, and you can afford $99–299/month (or have insurance coverage). Choose the ketogenic diet if: you are not eligible for or do not want prescription medications, you prefer a nonpharmaceutical intervention, you are willing to adhere to strict carbohydrate restriction, and you have a lower weight loss goal (10–20 pounds). Consider combining both if: you are already on a GLP-1 but want to maximize results, or you have plateaued and need a structured dietary push—but only under medical supervision.

Conclusion

In the head-to-head comparison for weight loss in 2026, GLP-1 medications outperform the ketogenic diet on every major metric: greater average weight loss, higher adherence at one year, and more predictable results. The data from the STEP and SURPASS trials is unequivocal—semaglutide and tirzepatide produce 3–4 times the loss of keto alone. However, keto remains a viable, accessible option for those who cannot or choose not to use medications. The emerging evidence also supports combination therapy for select individuals, provided they work with a healthcare team. Whichever path you take, the most important factor is consistency over time—and GLP-1s offer a pharmacological edge to help maintain that consistency.